SINGAPORE (May 22): Singapore eDevelopment (SeD), through its subsidiary, Global BioLife Inc., has initiated research on a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer’s, diabetes and cancer.

The research will be led by two-time Nobel Prize nominee, Daryl Thompson.

“Singapore Exchange-listed SeD said Thompson will leverage on his expertise in organic and carbohydrate chemistry and the use of pandemic technology in combating the Ebola virus in the research and development of this universal therapeutic drug platform, known as Linebacker,” says SeD in a filing this morning.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook